Canopy GrowthHAM:11L +2.12%59 Days Payable is 39.42 as of Mar. 2026, which is 37% below its 10-year median of 62.65. GuruFocus rates HAM:11L with a GF Score™ of 59/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Canopy Growth ranks worse than 82.21% on this metric.
The historical rank and industry rank for Canopy Growth's Days Payable or its related term are showing as below:
HAM:11L'
s Days Payable Range Over the Past 10 Years
Min: 36.2 Med: 62.65 Max: 1818.51
Current: 41.81
During the past 13 years, Canopy Growth's highest Days Payable was 1818.51. The lowest was 36.20. And the median was 62.65.
HAM:11L's Days Payable is ranked worse than 82.21% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs HAM:11L: 41.81
Canopy Growth's Days Payable
declined
from Mar. 2025 (47.05) to Mar. 2026 (39.42).
It may suggest that Canopy Growthaccelerated paying its suppliers.
Canopy Growth Days Payable Related Terms
Canopy Growth Days Payable Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Days Payable distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Canopy Growth's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (HAM:11L) has a Days Payable of 39.42 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Canopy Growth and its competitors. This is 37% below median its historical median of 62.65. Over the past decade, Canopy Growth's Days Payable has ranged from 36.20 to 1,818.51. According to the industry distribution chart, Canopy Growth ranks #758 out of 922 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Canopy Growth's Days Payable too high?
Canopy Growth's current Days Payable of 39.42 is 37% below median its 10-year median of 62.65. Over the past 10 years, this metric has ranged from a low of 36.20 to a high of 1,818.51. The Drug Manufacturers industry median Days Payable is 90.84. Canopy Growth's value of 39.42 is 56.6% below this industry median. Based on the distribution chart, Canopy Growth ranks #758 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #758 out of 922 companies for Days Payable. This places Canopy Growth in the lower half of its industry. The industry median Days Payable is 90.84. Canopy Growth's value of 39.42 is 56.6% below this benchmark. Historically, Canopy Growth's own Days Payable has ranged from 36.20 to 1,818.51 over the past decade. While the company's 10-year median is 62.65 vs. the industry median of 90.84, Canopy Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Days Payable of 39.42 is 56.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Days Payable is 39.42, which is 37% below median its own 10-year median of 62.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €0.88 — trading 37.2% above its estimated fair value. The current Days Payable is 39.42, which is 37% below median its 10-year median of 62.65 and 56.6% below the Drug Manufacturers industry median of 90.84. Canopy Growth's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current Days Payable is 39.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.88 is trading 37.2% above its estimated GF Value™ of €0.64.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for HAM:11L:
Days Payable: 39.42 (37% below median its 10-year median of 62.65)
GF Value™: €0.64 vs. price of €0.88 (37.2% above fair value)
Industry Position: 56.6% below the Drug Manufacturers median (#758 of 922)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score
Get the complete analysis for HAM:11L
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
